Benign prostatic hyperplasia

Nat Rev Dis Primers. 2016 May 5:2:16031. doi: 10.1038/nrdp.2016.31.

Abstract

Benign prostatic hyperplasia (BPH), which causes lower urinary tract symptoms (LUTS), is a common diagnosis among the ageing male population with increasing prevalence. Many risks factors, both modifiable and non-modifiable, can increase the risk of development and progression of BPH and LUTS. The symptoms can be obstructive (resulting in urinary hesitancy, weak stream, straining or prolonged voiding) or irritative (resulting in increased urinary frequency and urgency, nocturia, urge incontinence and reduced voiding volumes), or can affect the patient after micturition (for example, postvoid dribble or incomplete emptying). BPH occurs when both stromal and epithelial cells of the prostate in the transitional zone proliferate by processes that are thought to be influenced by inflammation and sex hormones, causing prostate enlargement. Patients with LUTS undergo several key diagnostic investigations before being diagnosed with BPH. Treatment options for men with BPH start at watchful waiting and progress through medical to surgical interventions. For the majority of patients, the starting point on the treatment pathway will be dictated by their symptoms and degree of bother.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Diet / adverse effects
  • Genetic Diseases, Inborn / complications
  • Humans
  • Inflammation / complications
  • Kallikreins / analysis
  • Kallikreins / blood
  • Lower Urinary Tract Symptoms / etiology
  • Male
  • Metabolic Syndrome / complications
  • Obesity / complications
  • Prevalence
  • Prostate-Specific Antigen / analysis
  • Prostate-Specific Antigen / blood
  • Prostatic Hyperplasia / complications*
  • Prostatic Hyperplasia / epidemiology
  • Prostatic Hyperplasia / physiopathology*
  • Risk Factors
  • Urinalysis

Substances

  • KLK3 protein, human
  • Kallikreins
  • Prostate-Specific Antigen